{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T02:42:02Z","timestamp":1783132922485,"version":"3.54.6"},"reference-count":41,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T00:00:00Z","timestamp":1724630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>The results of large cardiovascular studies indicate that SGLT-2 inhibitors may increase the risk of leg amputations. This study aims to investigate whether dapagliflozin therapy affects peripheral vascular oxygenation, i.e., microcirculation in the foot, as measured by transcutaneous oxygen pressure (TcPO2) in patients with type 2 diabetes (T2DM) and peripheral arterial disease (PAD) compared to patients without PAD. The patients with PAD were randomized into two groups. In the first 35 patients with PAD, dapagliflozin was added to the therapy; in the other 26 patients with PAD, other antidiabetic drugs were added to the therapy. Dapagliflozin was added to the therapy in all patients without PAD. TcPO2 measurement, Ankle Brachial Index (ABI), anthropometric measurements, and laboratory tests were performed. After a follow-up period of 119.35 days, there was no statistically significant difference in the reduction of mean TcPO2 values between the group with T2DM with PAD treated with dapagliflozin and the group with T2DM with PAD treated with other antidiabetic drugs (3.88 mm Hg, SD = 15.13 vs. 1.48 mm Hg, SD = 11.55, p = 0.106). Patients with control TcPO2 findings suggestive of hypoxia (TcPO2 &lt; 40 mm Hg) who were treated with dapagliflozin had a clinically significant decrease in mean TcPO2 of 10 mm Hg or more (15.8 mm Hg and 12.90 mm Hg). However, the aforementioned decrease in TcPO2 was not statistically significantly different from the decrease in TcPO2 in the group with PAD treated with other diabetic medications (p = 0.226, p = 0.094). Based on the available data, dapagliflozin appears to affect tissue oxygenation in T2DM with PAD. However, studies with a larger number of patients and a longer follow-up period are needed to determine the extent and significance of this effect.<\/jats:p>","DOI":"10.3390\/ph17091127","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T10:01:51Z","timestamp":1724666511000},"page":"1127","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Influence of Dapagliflozin on Foot Microcirculation in Patients with Type 2 Diabetes with and without Peripheral Arterial Disease\u2014A Pilot Study"],"prefix":"10.3390","volume":"17","author":[{"given":"Bo\u017eena","family":"Bradari\u0107","sequence":"first","affiliation":[{"name":"Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases, Merkur University Hospital, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4808-2968","authenticated-orcid":false,"given":"Tomislav","family":"Bulum","sequence":"additional","affiliation":[{"name":"Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases, Merkur University Hospital, 10000 Zagreb, Croatia"},{"name":"School of Medicine, University of Zagreb, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neva","family":"Brklja\u010di\u0107","sequence":"additional","affiliation":[{"name":"Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases, Merkur University Hospital, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u017deljko","family":"Mihaljevi\u0107","sequence":"additional","affiliation":[{"name":"Croatian Veterinary Institute, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslav","family":"Beni\u0107","sequence":"additional","affiliation":[{"name":"Croatian Veterinary Institute, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo\u017eo","family":"Bradari\u0107 Lisi\u0107","sequence":"additional","affiliation":[{"name":"Professional Study Program in Physiotherapy, University of Applied Health Sciences, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2337\/diacare.27.7.1591","article-title":"1999\u20132000 national health and nutrition examination survey. Prevalence of lower-extremity disease in the US adult population \u2265 40 years of age with and without diabetes: 1999\u20132000 national health and nutrition examination survey","volume":"27","author":"Gregg","year":"2004","journal-title":"Diabetes Care"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/1753-0407.12474","article-title":"Pathophysiology of peripheral arterial disease in diabetes mellitus","volume":"9","author":"Yang","year":"2016","journal-title":"J. Diabetes"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2337\/diacare.22.1.157","article-title":"Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings","volume":"22","author":"Vileikyte","year":"1999","journal-title":"Diabetes Care"},{"key":"ref_5","unstructured":"Hinchliffe, R.J., Andros, G., Apelqvist, J., Bakker, K., Fiedrichs, S., Lammer, J., Lepantalo, M., Mills, J.L., Reekers, J., and Shearman, C.P. A systematic review of the effectiveness of revascularization of the ulcerated foot in patients with diabetes and peripheral arterial disease, Diabetes\/Metab. Res. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.mcna.2013.03.007","article-title":"The diabetic foot. Preface","volume":"97","author":"Boulton","year":"2013","journal-title":"Med. Clin. N. Am."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1024\/0301-1526\/a000925","article-title":"The interrelationship between diabetes mellitus and peripheral arterial disease","volume":"50","author":"Stoberock","year":"2021","journal-title":"Vasa"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/s12933-023-02056-3","article-title":"Diabetic microvascular disease in non-classical beds: The hidden impact beyond the retina, the kidney, and the peripheral nerves","volume":"22","author":"Mauricio","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/1753-0407.13372","article-title":"Mechanisms of diabetic foot ulceration: A review","volume":"15","author":"Deng","year":"2023","journal-title":"J. Diabetes"},{"key":"ref_10","first-page":"43","article-title":"Transcutaneous oximetry in clinical practice: Con-sensus statements from an expert panel based on evidence","volume":"36","author":"Fife","year":"2009","journal-title":"Undersea Hyperb. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0950-821X(88)80015-X","article-title":"Transcutaneous oxygen tension exercise profile. A method for objectively assessing the results after reconstructive peripheral arterial surgery","volume":"2","author":"Larsen","year":"1988","journal-title":"Eur. J. Vasc. Surg."},{"key":"ref_12","first-page":"36","article-title":"The use of transcutaneous oximetry in the noninvasive vascular laboratory","volume":"11","author":"Rooke","year":"1992","journal-title":"Int. Angiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1067\/mva.2001.108011","article-title":"Interobserver and intraobserver reproducibility of peripheral blood and oxygen pressure measurements in the assessment of lower extremity arterial disease","volume":"33","author":"Ubbink","year":"2001","journal-title":"J. Vasc. Surg."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e002407","DOI":"10.1136\/bmjdrc-2021-002407","article-title":"Type 2 diabetes and the risk of cardiovascular events in peripheral artery disease versus coronary artery disease","volume":"9","author":"Sprenger","year":"2021","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee, ElSayed, N.A., Aleppo, G., Bannuru, R.R., Bruemmer, D., Collins, B.S., Ekhlaspour, L., Gaglia, J.L., Hilliard, M.E., and Johnson, E.L. (2023). 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes\u20142024. Diabetes Care, 47, S158\u2013S178.","DOI":"10.2337\/dc24-S009"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1161\/CIRCULATIONAHA.119.044775","article-title":"Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients with and Without Peripheral Artery Disease in DECLARE-TIMI 58","volume":"142","author":"Bonaca","year":"2020","journal-title":"Circulation"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e028739","DOI":"10.1161\/JAHA.122.028739","article-title":"Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA-CKD Trial","volume":"12","author":"Chertow","year":"2023","journal-title":"J. Am. Hear. Assoc."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"The EMPA-KIDNEY Collaborative Group, Herrington, W.G., Staplin, N., Wanner, C., Green, J.B., Hauske, S.J., Emberson, J.R., Preiss, D., Judge, P., and Mayne, K.J. (2023). Empagliflozin in Patients with Chronic Kidney Disease. N. Engl. J. Med., 388, 117\u2013127.","DOI":"10.1056\/NEJMoa2204233"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/ejhf.1432","article-title":"A trial to evaluate the effect of the sodium\u2013glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"100174","DOI":"10.1016\/j.wndm.2019.100174","article-title":"Change over time of the ankle brachial index","volume":"28","author":"Burke","year":"2019","journal-title":"Wound Med."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee, ElSayed, N.A., Aleppo, G., Bannuru, R.R., Bruemmer, D., Collins, B.S., Das, S.R., Ekhlaspour, L., Hilliard, M.E., and Johnson, E.L. (2023). 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes\u20142024. Diabetes Care, 47, S179\u2013S218.","DOI":"10.2337\/dc24-S010"},{"key":"ref_25","unstructured":"(2024, May 30). Forxiga 10 mg Film-Coated Tablets (07 March 2024). Available online: https:\/\/www.medicines.org.uk\/emc\/product\/7607\/smpc."},{"key":"ref_26","unstructured":"(2024, May 30). Jardiance 10 mg Film-Coated Tablets, (14 September 2023). Available online: https:\/\/www.medicines.org.uk\/emc\/product\/5441\/smpc#gref."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2337\/diacare.22.1.147","article-title":"Transcutaneous oxygen tension and toe blood pressure as predictors for outcome of diabetic foot ulcers","volume":"22","author":"Kalani","year":"1999","journal-title":"Diabetes Care"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Bulum, T., Brklja\u010di\u0107, N., Ivan\u010di\u0107, A.T., \u010cavlovi\u0107, M., Prka\u010din, I., and Tomi\u0107, M. (2024). In Association with Other Risk Factors, Smoking Is the Main Predictor for Lower Transcutaneous Oxygen Pressure in Type 2 Diabetes. Biomedicines, 12.","DOI":"10.3390\/biomedicines12020381"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/0741-5214(92)90196-F","article-title":"Predictive value of transcutaneous oxygen pressure and amputation success by use of supine and elevation measurements","volume":"15","author":"Bacharach","year":"1992","journal-title":"J. Vasc. Surg."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12933-017-0510-1","article-title":"A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation","volume":"16","author":"Ott","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12933-021-01264-z","article-title":"Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: A randomized active-controlled trial","volume":"20","author":"Sposito","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12933-017-0564-0","article-title":"Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study","volume":"16","author":"Shigiyama","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12933-017-0621-8","article-title":"Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: A pilot study","volume":"16","author":"Solini","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"bvz017","DOI":"10.1210\/jendso\/bvz017","article-title":"Effects of Dapagliflozin on Endothelial Dysfunction in Type 2 Diabetes with Established Ischemic Heart Disease (EDIFIED)","volume":"4","author":"Zainordin","year":"2019","journal-title":"J. Endocr. Soc."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1093\/cvr\/cvx093","article-title":"The microcirculation: A key player in obesity-associated cardiovascular disease","volume":"113","author":"Sorop","year":"2017","journal-title":"Cardiovasc. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.36740\/WLek202109103","article-title":"State of Cutaneous Microcirculation in Patients with Obesity","volume":"74","author":"Andreieva","year":"2021","journal-title":"Wiad. Lek."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","article-title":"Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects","volume":"139","author":"Sano","year":"2019","journal-title":"Circulation"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.2174\/13816128113199990474","article-title":"Dipeptidyl-peptidase 4 inhibition: Linking metabolic control to cardiovascular protection","volume":"20","author":"Avogaro","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"E173","DOI":"10.1152\/ajpendo.00287.2021","article-title":"Metformin improves skeletal muscle microvascular insulin resistance in metabolic syndrome","volume":"322","author":"Jahn","year":"2021","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_40","first-page":"3591","article-title":"Metformin improves retinal capillary perfusion in diabetic mice","volume":"59","author":"Qiao","year":"2018","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Sch\u00f6nborn, M., Gregorczyk-Maga, I., Batko, K., Bogucka, K., Maga, M., P\u0142otek, A., Pasieka, P., S\u0142owi\u0144ska-Solnica, K., and Maga, P. (2023). Circulating Angiogenic Factors and Ischemic Diabetic Foot Syndrome Advancement\u2014A Pilot Study. Biomedicines, 11.","DOI":"10.3390\/biomedicines11061559"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/9\/1127\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:42:57Z","timestamp":1760110977000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/9\/1127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,26]]},"references-count":41,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["ph17091127"],"URL":"https:\/\/doi.org\/10.3390\/ph17091127","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,26]]}}}